DE3780925D1 - Nasale formulierungen und verfahren zu deren herstellung. - Google Patents

Nasale formulierungen und verfahren zu deren herstellung.

Info

Publication number
DE3780925D1
DE3780925D1 DE8787311054T DE3780925T DE3780925D1 DE 3780925 D1 DE3780925 D1 DE 3780925D1 DE 8787311054 T DE8787311054 T DE 8787311054T DE 3780925 T DE3780925 T DE 3780925T DE 3780925 D1 DE3780925 D1 DE 3780925D1
Authority
DE
Germany
Prior art keywords
production
nasal formulations
phosphalidylcholine
phospholipid
lecithin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE8787311054T
Other languages
English (en)
Other versions
DE3780925T2 (de
Inventor
Philip Edgar Hansen
Anders Robert Sorensen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DK604286A external-priority patent/DK604286D0/da
Priority claimed from DK370087A external-priority patent/DK370087D0/da
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Application granted granted Critical
Publication of DE3780925D1 publication Critical patent/DE3780925D1/de
Publication of DE3780925T2 publication Critical patent/DE3780925T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Otolaryngology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE8787311054T 1986-12-16 1987-12-15 Nasale formulierungen und verfahren zu deren herstellung. Expired - Lifetime DE3780925T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK604286A DK604286D0 (da) 1986-12-16 1986-12-16 Praeparat
DK370087A DK370087D0 (da) 1987-07-16 1987-07-16 Produkt med forbedrede egenskaber

Publications (2)

Publication Number Publication Date
DE3780925D1 true DE3780925D1 (de) 1992-09-10
DE3780925T2 DE3780925T2 (de) 1992-12-24

Family

ID=26067181

Family Applications (1)

Application Number Title Priority Date Filing Date
DE8787311054T Expired - Lifetime DE3780925T2 (de) 1986-12-16 1987-12-15 Nasale formulierungen und verfahren zu deren herstellung.

Country Status (22)

Country Link
EP (1) EP0272097B1 (de)
JP (1) JPH0768149B2 (de)
KR (1) KR890700036A (de)
CN (1) CN1034105C (de)
AT (1) ATE79039T1 (de)
AU (1) AU606121B2 (de)
CA (1) CA1326210C (de)
CS (1) CS273139B1 (de)
DE (1) DE3780925T2 (de)
ES (1) ES2044957T3 (de)
FI (1) FI94024C (de)
GR (1) GR3005381T3 (de)
HU (1) HU209247B (de)
IE (1) IE61110B1 (de)
IL (1) IL84835A (de)
MX (1) MX9203640A (de)
NO (1) NO175566C (de)
NZ (1) NZ222907A (de)
PT (1) PT86370B (de)
RU (1) RU1837869C (de)
WO (1) WO1988004556A1 (de)
YU (1) YU46978B (de)

Families Citing this family (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5690954A (en) * 1987-05-22 1997-11-25 Danbiosyst Uk Limited Enhanced uptake drug delivery system having microspheres containing an active drug and a bioavailability improving material
US5641474A (en) * 1987-06-24 1997-06-24 Autoimmune, Inc. Prevention of autoimmune diseases by aerosol administration of autoantigens
US5571500A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases through administration by inhalation of autoantigens
US5571499A (en) * 1987-06-24 1996-11-05 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
US5849298A (en) * 1987-06-24 1998-12-15 Autoimmune Inc. Treatment of multiple sclerosis by oral administration of bovine myelin
US5645820A (en) * 1987-06-24 1997-07-08 Autoimmune, Inc. Treatment of autoimmune diseases by aerosol administration of autoantigens
PT88490B (pt) * 1987-09-14 1992-11-30 Novo Nordisk As Processo para a preparacao de composicoes farmaceuticas para libertacao nao-enterica trans-mucosa contendo monossacaridos ou oligossacaridos
GB8723846D0 (en) * 1987-10-10 1987-11-11 Danbiosyst Ltd Bioadhesive microsphere drug delivery system
ES2061688T3 (es) * 1987-11-13 1994-12-16 Smithkline Beecham Farma Composiciones farmaceuticas que comprenden una calcitonina y un glicirricinato como mejorador de la absorcion.
GB8822857D0 (en) * 1988-09-29 1988-11-02 Patralan Ltd Pharmaceutical formulations
ES2089011T3 (es) * 1989-02-17 1996-10-01 Liposome Co Inc Excipiente lipidico de administracion nasal y aplicacion topica.
IT8920486A0 (it) * 1989-05-12 1989-05-12 Isf Spa Composizioni farmaceutiche.
US5725871A (en) * 1989-08-18 1998-03-10 Danbiosyst Uk Limited Drug delivery compositions comprising lysophosphoglycerolipid
GB8918879D0 (en) * 1989-08-18 1989-09-27 Danbiosyst Uk Pharmaceutical compositions
GB9007052D0 (en) * 1990-03-29 1990-05-30 Skua Investments Ltd Pharmaceutical formulations
GB9012663D0 (en) * 1990-06-07 1990-08-01 Erba Carlo Spa Galenic formulations containing cyclodextrins
IL99699A (en) * 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
IT1250691B (it) * 1991-07-22 1995-04-21 Giancarlo Santus Composizioni terapeutiche per somministrazione intranasale comprendenti ketorolac.
DK36492D0 (da) * 1992-03-19 1992-03-19 Novo Nordisk As Praeparat
EP0566135A1 (de) * 1992-04-17 1993-10-20 Takeda Chemical Industries, Ltd. Transmucosale Zubereitungen enthaltend ein Peptid und ein Cytidinderivat
DE4214953C2 (de) * 1992-05-06 1995-05-18 Arrowdean Ltd Arzneimittel zur Erhöhung des Testosteronspiegels
DE4218291A1 (de) * 1992-06-03 1993-12-09 Mattern Et Partner Pharmazeuti Dosierspray für pernasale Applikation
SI9300468A (en) * 1992-10-14 1994-06-30 Hoffmann La Roche Injectable composition for the sustained release of biologically active compounds
US6794357B1 (en) 1993-06-24 2004-09-21 Astrazeneca Ab Compositions for inhalation
IS1796B (is) * 1993-06-24 2001-12-31 Ab Astra Fjölpeptíð lyfjablanda til innöndunar sem einnig inniheldur eykjaefnasamband
US6632456B1 (en) 1993-06-24 2003-10-14 Astrazeneca Ab Compositions for inhalation
US5506203C1 (en) * 1993-06-24 2001-02-06 Astra Ab Systemic administration of a therapeutic preparation
US5830853A (en) * 1994-06-23 1998-11-03 Astra Aktiebolag Systemic administration of a therapeutic preparation
US5747445A (en) * 1993-06-24 1998-05-05 Astra Aktiebolag Therapeutic preparation for inhalation
TW402506B (en) * 1993-06-24 2000-08-21 Astra Ab Therapeutic preparation for inhalation
KR100419037B1 (ko) 1994-03-07 2004-06-12 넥타르 테라퓨틱스 폐를통한인슐린의전달방법및그조성물
US6165976A (en) * 1994-06-23 2000-12-26 Astra Aktiebolag Therapeutic preparation for inhalation
CA2201358C (en) * 1994-09-30 2004-06-08 Jurgen Regenold Pharmaceutical composition
SE9404468D0 (sv) * 1994-12-22 1994-12-22 Astra Ab Powder formulations
US6524557B1 (en) 1994-12-22 2003-02-25 Astrazeneca Ab Aerosol formulations of peptides and proteins
US5869602A (en) 1995-03-17 1999-02-09 Novo Nordisk A/S Peptide derivatives
US5780014A (en) * 1995-04-14 1998-07-14 Inhale Therapeutic Systems Method and apparatus for pulmonary administration of dry powder alpha 1-antitrypsin
US5653987A (en) * 1995-05-16 1997-08-05 Modi; Pankaj Liquid formulations for proteinic pharmaceuticals
US5856446A (en) * 1995-07-07 1999-01-05 Autoimmune Inc. Method of treating rheumatoid arthritis with low dose type II collagen
JPH11292787A (ja) * 1995-08-15 1999-10-26 Asahi Chem Ind Co Ltd 生理活性ペプチドを含有する経粘膜投与製剤
US5985309A (en) * 1996-05-24 1999-11-16 Massachusetts Institute Of Technology Preparation of particles for inhalation
US5874064A (en) * 1996-05-24 1999-02-23 Massachusetts Institute Of Technology Aerodynamically light particles for pulmonary drug delivery
US6652837B1 (en) 1996-05-24 2003-11-25 Massachusetts Institute Of Technology Preparation of novel particles for inhalation
EP1826216A1 (de) 1996-08-30 2007-08-29 Novo Nordisk A/S Glp-1-Derivate
US6017545A (en) * 1998-02-10 2000-01-25 Modi; Pankaj Mixed micellar delivery system and method of preparation
DE69942306D1 (de) 1998-02-27 2010-06-10 Novo Nordisk As Abkömmlinge von glp-1 analogen
JP2002506792A (ja) 1998-02-27 2002-03-05 ノボ ノルディスク アクティーゼルスカブ Ｎ末端修飾ｇｌｐ−１誘導体
ATE466026T1 (de) 1998-02-27 2010-05-15 Novo Nordisk As Derivate von glp-1 und exendin mit verlängertem wirkdauer-profil
TWI243687B (en) 1998-04-21 2005-11-21 Teijin Ltd Pharmaceutical composition for application to mucosa
EP1306091A3 (de) 1998-07-31 2003-05-21 Novo Nordisk A/S Stimulation der Beta-Zellen Vermehrung
US6290987B1 (en) 1998-09-27 2001-09-18 Generex Pharmaceuticals, Inc. Mixed liposome pharmaceutical formulation with amphiphiles and phospholipids
US6436367B1 (en) 1998-12-21 2002-08-20 Generex Pharmaceuticals Inc. Aerosol formulations for buccal and pulmonary application
US6849263B2 (en) 1998-12-21 2005-02-01 Generex Pharmaceutical Incorporated Pharmaceutical compositions for buccal delivery of pain relief medications
US6271200B1 (en) 1998-12-21 2001-08-07 Generex Pharmaceuticals Inc. Proteinic drug delivery system using aerosolized membrane-mimetic amphiphiles
US7087215B2 (en) 1998-12-21 2006-08-08 Generex Pharmaceuticals Incorporated Methods of administering and enhancing absorption of pharmaceutical agents
US6540982B1 (en) * 2000-01-25 2003-04-01 Aeropharm Technology Incorporated Medical aerosol formulation
AU2001237254A1 (en) 2000-03-08 2001-09-17 Novo-Nordisk A/S Lowering serum lipids
GB0027357D0 (en) 2000-11-09 2000-12-27 Bradford Particle Design Plc Particle formation methods and their products
JP2004535432A (ja) * 2001-06-22 2004-11-25 ベントレー ファーマシューティカルズ インコーポレイテッド 医薬組成物
US7244703B2 (en) 2001-06-22 2007-07-17 Bentley Pharmaceuticals, Inc. Pharmaceutical compositions and methods for peptide treatment
GB0205327D0 (en) * 2002-03-06 2002-04-17 Glaxo Group Ltd compounds
US9339459B2 (en) 2003-04-24 2016-05-17 Nektar Therapeutics Particulate materials
DK2275439T3 (da) 2003-08-05 2014-05-12 Novo Nordisk As Hidtil ukendte insulinderivater
EP2264065B1 (de) 2003-08-05 2017-03-08 Novo Nordisk A/S Neue insulinderivate
BR122019021416A2 (de) 2003-09-19 2019-12-21
US7625865B2 (en) 2004-03-26 2009-12-01 Universita Degli Studi Di Parma Insulin highly respirable microparticles
CN1299770C (zh) * 2004-05-31 2007-02-14 刘近周 多功能鼻腔和鼻窦洁疗液
BRPI0518761A2 (pt) 2004-12-02 2008-12-09 Domantis Ltd fusço de droga, conjugado de droga, Ácido nucleico recombinante, construÇço de Ácido nucleico, cÉlula hospedeira, mÉtodo para produzir uma fusço de droga, composiÇço farmacÊutica, droga, mÉtodo de tratamento e/ou prevenÇço de uma condiÇço em um paciente, mÉtodo de retardo ou prevenÇço de progressço de doenÇa, e, mÉtodo para diminuir a absorÇço de alimentos por um paciente
US8067362B2 (en) 2005-02-02 2011-11-29 Novo Nordisk As Insulin derivatives
EP2292653B1 (de) 2005-02-02 2014-05-21 Novo Nordisk A/S Neuartige Insulinderivate
DE602007009496D1 (de) 2006-02-27 2010-11-11 Novo Nordisk As Insulinderivate
JP5269767B2 (ja) 2006-05-09 2013-08-21 ノボ・ノルデイスク・エー／エス インスリン誘導体
EP2024390B1 (de) 2006-05-09 2015-08-19 Novo Nordisk A/S Insulinderivate
CN101743252A (zh) 2007-07-16 2010-06-16 诺沃-诺迪斯克有限公司 蛋白酶稳定化的、peg化的胰岛素类似物
JP5721432B2 (ja) 2007-08-15 2015-05-20 ノボ・ノルデイスク・エー／エス アミノ酸含有アルキレングリコール反復単位を含むアシル部を有するインスリン
EP2178912B1 (de) 2007-08-15 2015-07-08 Novo Nordisk A/S Insulinanaloge mit acyl- und alkylenglycolteilen
JP5749155B2 (ja) 2008-03-18 2015-07-15 ノボ・ノルデイスク・エー／エス プロテアーゼ安定化アシル化インスリンアナログ
AU2009231439A1 (en) 2008-03-31 2009-10-08 Glaxo Group Limited Drug fusions and conjugates
EP2262539B1 (de) 2008-04-01 2015-07-15 Novo Nordisk A/S Insulin-albumin-konzentrate
US8277781B2 (en) 2009-03-13 2012-10-02 Luitpold Pharmaceuticals, Inc. Device for intranasal administration
US8551454B2 (en) 2009-03-13 2013-10-08 Luitpold Pharmaceuticals, Inc. Device for intranasal administration
JP2012521971A (ja) 2009-03-27 2012-09-20 グラクソ グループ リミテッド 薬物融合体および複合体
CN102666586A (zh) 2009-09-30 2012-09-12 葛兰素集团有限公司 具有延长的半衰期的药物融合体和缀合物
EP2632478B1 (de) 2010-10-27 2019-07-24 Novo Nordisk A/S Behandlung von diabetes mellitus mit in variierenden injektionsintervallen verabreichten insulininjektionen
US9808030B2 (en) 2011-02-11 2017-11-07 Grain Processing Corporation Salt composition
WO2012136790A1 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Compositions comprising fusion proteins or conjugates with an improved half -life
WO2012136792A2 (en) 2011-04-07 2012-10-11 Glaxo Group Limited Cck compositions
CN104244981A (zh) 2011-12-09 2014-12-24 诺和诺德A/S Glp-1激动剂
BR112014026442A8 (pt) 2012-05-01 2018-01-16 Novo Nordisk As combinação para alcançar o controle glicêmico, seu uso, e composição farmacêutica.
WO2014093688A1 (en) 2012-12-12 2014-06-19 1Massachusetts Institute Of Technology Compositions and methods for functional nucleic acid delivery
US9867869B2 (en) 2012-12-12 2018-01-16 Massachusetts Institute Of Technology Insulin derivatives for diabetes treatment
WO2015081891A1 (en) 2013-12-06 2015-06-11 Baikang (Suzhou) Co., Ltd Bioreversable promoieties for nitrogen-containing and hydroxyl-containing drugs
CA2975562C (en) * 2015-02-17 2020-04-28 Eli Lilly And Company Nasal powder formulation for treatment of hypoglycemia
EP3873434A1 (de) 2018-11-04 2021-09-08 Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Nasale zusammensetzungen und verfahren

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3594476A (en) * 1969-05-12 1971-07-20 Massachusetts Inst Technology Submicron aqueous aerosols containing lecithin
GB1527605A (en) * 1975-08-20 1978-10-04 Takeda Chemical Industries Ltd Insulin preparation for intranasal administration
NL193099C (nl) * 1981-10-30 1998-11-03 Novo Industri As Gestabiliseerde insuline-oplossing.
DE3228629A1 (de) * 1982-07-31 1984-02-02 Reifenrath, Rainer Richard Otto, Dr., 3104 Unterlüß Pharmazeutisches erzeugnis zur behandlung der atemwege und verfahren zu seiner herstellung
DE3323389A1 (de) * 1983-06-29 1985-01-10 B. Braun Melsungen Ag, 3508 Melsungen Auf schleimhaeute des mundes, der nase und/oder des rachens wirkende arzneimittel auf der basis von heparin und tensiden
GB8327330D0 (en) * 1983-10-12 1983-11-16 Parsons W J Membrane analogue emulsions
WO1985005029A1 (en) * 1984-05-09 1985-11-21 Medaphore Inc. Oral insulin and a method of making the same
GB8501015D0 (en) * 1985-01-16 1985-02-20 Riker Laboratories Inc Drug
EP0200383A3 (de) * 1985-04-15 1987-09-02 Eli Lilly And Company Verfahren zur Verabreichung von Insulin
IT1187743B (it) * 1985-09-26 1987-12-23 Prodotti Formenti Srl Composizioni farmaceutiche a base di destrorfano per applicazione instranasale

Also Published As

Publication number Publication date
ES2044957T3 (es) 1994-01-16
CS273139B1 (en) 1991-03-12
HUT57592A (en) 1991-12-30
EP0272097A3 (en) 1988-08-24
CN87108340A (zh) 1988-07-13
EP0272097B1 (de) 1992-08-05
NO175566C (no) 1994-11-02
NO175566B (no) 1994-07-25
KR890700036A (ko) 1989-03-02
DE3780925T2 (de) 1992-12-24
HU209247B (en) 1994-04-28
IE61110B1 (en) 1994-10-05
YU228487A (en) 1988-12-31
FI883783A0 (fi) 1988-08-15
IE873408L (en) 1988-06-16
JPH0768149B2 (ja) 1995-07-26
JPH01501550A (ja) 1989-06-01
EP0272097A2 (de) 1988-06-22
FI94024C (fi) 1995-07-10
NZ222907A (en) 1990-08-28
PT86370A (en) 1988-01-01
GR3005381T3 (de) 1993-05-24
RU1837869C (ru) 1993-08-30
NO883627D0 (no) 1988-08-15
NO883627L (no) 1988-08-15
MX9203640A (es) 1992-09-01
CN1034105C (zh) 1997-02-26
CA1326210C (en) 1994-01-18
PT86370B (pt) 1990-11-20
WO1988004556A1 (en) 1988-06-30
AU606121B2 (en) 1991-01-31
AU1085888A (en) 1988-07-15
FI94024B (fi) 1995-03-31
ATE79039T1 (de) 1992-08-15
CS930487A1 (en) 1990-07-12
FI883783A (fi) 1988-08-15
IL84835A0 (en) 1988-06-30
YU46978B (sh) 1994-09-09
IL84835A (en) 1994-01-25

Similar Documents

Publication Publication Date Title
DE3780925D1 (de) Nasale formulierungen und verfahren zu deren herstellung.
FI871750A (fi) Nasal administration av laekemedel.
DE3671367D1 (de) Arzneistoffadsorbate und deren herstellung.
DE68929422D1 (de) Nukleophile polysubstituierte Arylacridiniumester, deren Konjugate, sowie deren Herstellung und Verwendungen
ATE109971T1 (de) Verabreichung von arzneimitteln über die lungen.
DE3776966D1 (de) Funktionelle gruppen tragende liposome und verfahren zu deren herstellung.
FR2578540B1 (fr) Nouveaux derives de pyridylmethoxy- et -methylmercaptoanilines, utilses notamment comme antiasthmatiques, leur fabrication et medicaments les contenant
FI950909A (fi) Rasvahappojohdannaisia
DE3575929D1 (de) Methylenbisphosphonsaeure-derivate, deren herstellung und arzneimittel.
DE3772482D1 (de) Loesungen von oxazaphosphorinen mit verbesserter stabilitaet und verfahren zu deren herstellung.
DE69001573D1 (de) Zusammensetzungen zur herstellung von in dosisformen aktiven vitaminen d3 sowie verfahren zur herstellung stabiler, in dosisformen aktiver vitamine d3 unter deren verwendung.
EP0218679A4 (de) Aerosolmittel zur nasenverstäubung von vitamin b 12.
DE3872620D1 (de) (arylsulphonyl)-nitromethane, verfahren zu deren herstellung und deren verwendung in pharmazeutischen zusammensetzungen.
DE3777367D1 (de) Hirudin-variante, deren verwendung und herstellung.
DE3668366D1 (de) Manschettenverbindung und deren herstellungsverfahren.
DE3675722D1 (de) 4-alkoxy-3-pyrrolin-2-on-1-yl-essigsaeurealkyl- bzw. -benzylester sowie deren herstellung.
ATE118348T1 (de) Liposome hoher stabilität und verfahren zur herstellung und verwendung.
MX9305578A (es) Adsorbato a base de una mezcla de sustancias auxiliares y un principio activo no solido para la produccion de preparados medicamentosos.
DE3583015D1 (de) Phospholipidkonjugate und deren herstellung.
DE3764233D1 (de) Cyclopentylaether, deren herstellung und pharmazeutische formulierung.
ATE58527T1 (de) 4-alkoxy-3-pyrrolin-2-on-1-yl-essigsaeurealkylbzw. -benzylester sowie deren herstellung.
ATE58530T1 (de) 1,4-dihydropyridinverbindungen und ihre herstellung und pharmazeutische formulierung.
DE3675747D1 (de) 1,4-dihydropyridinverbindungen und ihre herstellung und pharmazeutische formulierung.
AR003950A1 (es) Medicamento que comprende un surfactante pulmonar de origen porcino, metodos de obtencion del surfactante pulmonar y del medicamento, y su uso de dicho surfactante pulmonar para la preparación de dicho medicamento

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee